Status: Recruiting
KAN-004 for Immune-Related Diarrhea or Colitis
The goal of this clinical trial is to evaluate the safety and tolerability of KAN-004 in patients with immune-related colitis.
Participants needed: 21
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Centre hospitalier de l'Université de Montréal (CHUM)Updated: Apr 13, 2026Locations: 1
Eligibility criteria
Diagnosis of solid tumor treated with immune checkpoint inhibitor (≥1 cycle, ≤18... [+6]
Prior/concurrent malignancy that could interfere with safety/efficacy assessment... [+6]